National Hospital Organisation Nagoya Medical Centre   Report issue

Academic/Hospital Phase 1 Phase 2
Founded: Nagoya Japan (1968)

Organization Overview

First Clinical Trial
2004
NCT00245089
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

National Hospital Organization Nagoya Medical Center | National Hospital Orgnization Nagoya Medical Center

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Non-Small-Cell Lung (Phase 2)

Down Syndrome (Phase 2)

Hypertension (Phase 2)

Hypertension, Pulmonary (Phase 2)

Leukemia (Phase 2)

Leukemia, Lymphoid (Phase 2)

Lung Neoplasms (Phase 2)

Neoplasms (Phase 1)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)

Rhabdomyosarcoma (Phase 2)

Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 6
  • # of Trial APIs: 16